Malignant disease accounts for approximately 10% of all cases of ascites, which is defined as an abnormal accumulation of fluid in the peritoneal cavity. It most commonly occurs in advanced ovarian carcinoma as well as in breast, lung, and gastrointestinal cancers, although 1 in 5 patients with malignant ascites may have cancers of unknown origin. Troublesome symptoms include abdominal distension, early satiety, dyspnea, nausea, and reduced mobility.
The pathophysiology of malignant ascites is complex and multifactorial. Ascites may result from the mechanical obstruction of lymphatic drainage by tumor cells leading to incomplete absorption of intraperitoneal fluid and protein, especially in patients with breast cancer and lymphoma. Due to the high protein content of the fluid, increased vascular permeability has been implicated in the etiology. The accumulation of ascites from obstructed lymphatics can lead to a reduction in the circulating blood volume which, in turn, activates the rennin-angiotensin-aldosterone system causing sodium retention. It is for this reason that sodium restriction and diuretics are most often used to manage ascites. 1, 2 There is no generally accepted gold standard for the management of malignant ascites. Paracentesis and diuretics are most commonly employed followed by peritoneovenous (PV) shunting or permanent drainage, dietary measures, and systemic or intraperitoneal chemotherapy.
In 2006, Becker et al 2 published an article trying to make sense of the treatment of malignant ascites as well as offering some management guidelines. They undertook a literature search for articles published between 1966 and August 2005, utilizing strict inclusion criteria including the use of abdominal paracentesis, diuretics, and PV shunting in the treatment of symptomatic ascites. Thirty-two studies were identified and none were randomized clinical trials.
Abdominal paracentesis provides symptomatic relief in 90% of the patients. Complications of this procedure include secondary peritonitis, pulmonary embolism, and hypotension. It is this last complication that is most concerning to clinicians especially with regard to infusion fluids or albumin during the procedure. Becker et al 2 note that studies in the setting of liver disease report that up to 5 L of ascitic fluid can be removed quickly without the risk of significantly affecting the plasma volume or kidney function. Also, symptomatic improvement occurs with the removal of a few liters, ranging from 0.8 to 15 L, with a mean of 5.3 L and median of 4.9 L.
In this issue, Zama and Edgar 3 report a case series of homebased paracentesis in 6 hospice patients. Of 6 patients, 4 had chronic liver disease and the remaining 2 patients had breast cancer and soft tissue sarcoma, respectively. All had failed diuretics and prior paracentesis. The median survival from last paracentesis to death was 38.4 days with a range of 6 to 57 days. The procedure was done without ultrasound guidance and any untoward complications. In this first of a kind report, the authors conclude that home-based therapeutic paracentesis in symptomatic patients is both safe and effective, providing less burden to the patient and family.
The use of diuretics in the management of malignant ascites is inconsistent. As noted by Becker et al, 2 a survey of physicians on the use of diuretics showed that 61% prescribed them, however, only 45% felt them to be effective. Overall, slightly less than half (43%) of the patients respond no matter what the underlying tumor be. Spironolactone is a commonly used diuretic and raises the plasma rennin level which, as noted previously, can be lowered causing sodium retention. Furthermore, there is a suggestion that ascites due to extensive liver metastases responds better to diuretics than ascites caused by peritoneal carcinomatosis or chylous ascites.
After failing paracentesis and diuretics, PV shunting becomes a consideration. The PV shunts were first developed to control the ascites associated with cirrhosis and later used in patients with malignant ascites. The concept of the PV shunt is quite simple and involves draining the fluid in the abdominal cavity back into the systemic circulation. There are 2 types of shunts, that is, the LeVeen and the Denver shunts. The LeVeen shunt drains the fluid into the superior vena cava via a 1-way valve opening at a pressure of 3 cm H 2 O. Although the Denver shunt was developed to prevent occlusion by proteinaceous material, the valve opens at a positive pressure gradient of 1 cm H 2 O preventing detectable reflux. Contraindications include hemorrhagic ascites, high ascitic fluid protein content (greater than 4.5 g/L), loculated ascites, portal hypertension, bleeding disorders, and cardiac and renal failures. About 6% of the patients will sustain a major complication such as pulmonary edema, pulmonary emboli, clinically relevant disseminated intravascular coagulation (DIC), and infection. When PV shunting was initially reported, there was great concern that malignant cells would be introduced into the systemic circulation, resulting in the occurrence of blood borne metastases. However, this has not been found at autopsy.
The success rate of these shunts in controlling ascites is approximately 75%. The best response, that is, over 50%, is generally seen in patients with ovarian and breast cancer. Only 10% to 15% response is noted in patients with malignant ascites and gastrointestinal cancer undergoing PV shunting. Because of this low response, PV shunting is not generally utilized in these patients. The controversy about shunt insertion revolves around the patient's expected survival. Considering patient selection, median survival time in patients with malignant ascites fluctuates between 52 and 266 days. Therefore, PV shunts should be used in those patients who have failed diuretics and repeated paracentesis and will live long enough to benefit symptomatically from this procedure. How long this will be is generally not agreed upon, with some suggesting more than 1 month and others suggesting a survival of more than 3 months. 2 A recent novel approach is the targeting of vascular endothelial growth factor (VEGF) in the management of malignant ovarian ascites. The VEGF is important for tumor neovacularization resulting in tumor growth and metastases and also increases vascular permeability leading to ascites formation. Small case studies have reported the successful role of the VEGF-targeted antibody, bevacizumab, in palliating symptomatic ascites in patients with refractory ovarian carcinoma requiring frequent paracentesis. Aflibercept is a soluble circulating VEGF receptor decoy that acts as a VEGF trap. 1 It was this drug that Gotlieb et al 4 studied in a phase 2, randomized, double-blind, placebo-controlled trial in patients with recurrent, symptomatic malignant ascites due to advanced ovarian cancer. The time to repeat paracentesis and paracentesis-free survival was significantly longer with aflibercept than with the placebo. In addition, the 60-day frequency of paracentesis was significantly lower with aflibercept than with placebo; however, the overall survival was not significantly different between the 2 groups. Furthermore, there were more fatal gastrointestinal perforations with aflibercept than with the placebo. This is similar to the problem with gastrointestinal perforations reported with the use of bevacizumab in these patients. Although the trial demonstrated the effectiveness of VEGF blockade in the reduction of ascites formation, it came with a price. As stressed by the authors, the recorded bowel perforations, including deaths, point to an unfavorable benefit to risk balance for using this VEGF trap in heavily, pretreated patients with advanced ovarian cancer. hypotensive, dehydrated, or has severe renal disease. The only studied replacement therapy is the infusion of 5% dextrose. 4. The PV shunting may be considered if repeated paracentesis is needed. Complications including pulmonary edema, pulmonary embolism, DIC, and infection occur in 6% of the patients. 5. There are no randomized controlled trials evaluating the effectiveness of diuretics in malignant ascites. Patients with extensive hepatic metastases appear to respond better to diuretics than patients with ascites due to peritoneal carcinomatosis for chylous ascites. 6. Choice of diuretics is not evaluated. The efficacy of diuretics depends on the plasma rennin/aldosterone concentration, and aldosterone antagonists like spironolactone should be used either alone or in combination with a loop diuretic. 7. Dose regimens of diuretics are not evaluated in patients with malignant ascites.
